

VANTA BIOSCIENCE LIMITED									
NO.02/G/308/G NO.3/FF/SF/1-20-248 UMAJAY COMPLEX RASOOLPURA SECUNDERABAD - 500003									
CIN L74999TG2016PLC109280									
STATEMENT OF STANDALONE AND CONSOLIDATED UNAUDITED RESULTS FOR THE HALF YEAR ENDED 30th SEPTEMBER 2022									
Sr.No	Particulars	(Rupees. In Lacs)				(Rupees. In Lacs)			
		STANDALONE				CONSOLIDATED			
		HALF YEAR ENDED		YEAR ENDED		HALF YEAR ENDED		YEAR ENDED	
		30.09.2022	30.09.2021	31.03.2022	31.03.2022	30.09.2022	30.09.2021	31.03.2022	31.03.2022
(Un Audited)	(Un Audited)	(Audited)	(Audited)	(Un Audited)	(Un Audited)	(Audited)	(Audited)		
1	<b>Income</b>								
	Revenue from Operation	170.50	538.21	396.77	934.98	282.35	538.22	430.53	968.75
	Other Income	0.60	2.10	14.67	16.77	1.09	2.17	40.14	42.31
	<b>Total Revenue</b>	<b>171.10</b>	<b>540.31</b>	<b>411.44</b>	<b>951.75</b>	<b>283.44</b>	<b>540.39</b>	<b>470.67</b>	<b>1011.06</b>
2	<b>Expenses</b>								
	a) Cost of material Consumed	19.47	55.66	6.66	62.32	41.28	55.66	14.55	70.21
	b) Employee Benfit Expenses	61.12	184.76	114.37	299.13	113.07	184.76	123.88	308.64
	c) Financial Cost	119.75	102.24	109.14	211.38	248.21	114.30	120.40	234.70
	d) Depreciation and amortization Exp	62.44	65.82	65.79	131.61	131.08	65.82	65.79	131.61
	e) other expenses	57.63	100.02	133.33	233.35	182.76	148.74	94.33	243.07
	<b>Total Expenses</b>	<b>320.41</b>	<b>508.50</b>	<b>429.29</b>	<b>937.79</b>	<b>716.39</b>	<b>569.28</b>	<b>418.94</b>	<b>988.22</b>
3	<b>Profit/(Loss) from ordinary activities before Exceptional Items (1-2)</b>	<b>-149.30</b>	<b>31.81</b>	<b>-17.85</b>	<b>13.96</b>	<b>-432.95</b>	<b>-28.89</b>	<b>51.73</b>	<b>22.84</b>
4	Exceptional Items Income /(Expenses)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
5	<b>Profit/(Loss) from ordinary activities before tax (3+4)</b>	<b>-149.30</b>	<b>31.81</b>	<b>-17.85</b>	<b>13.96</b>	<b>-432.95</b>	<b>-28.89</b>	<b>51.73</b>	<b>22.84</b>
6	Minority Interest	0.00	0.00	0.00	0.00	-186.30	-33.19	37.84	4.65
7	<b>Net Profit/(Loss) after Minority Interest (5-6)</b>	<b>-149.30</b>	<b>31.81</b>	<b>-17.85</b>	<b>13.96</b>	<b>-246.65</b>	<b>4.30</b>	<b>13.89</b>	<b>18.19</b>
8	<b>Tax Expenses</b>								
	a) Current Tax	0.00	(5.04)	2.66	(2.38)	0.00	(0.39)	-5.25	(5.64)
	b) MAT Credit Availed	0.00	0.97	1.41	2.38	0.00	0.97	1.41	2.38
	c) Deferred Tax	(1.41)	(2.91)	(3.20)	(6.11)	(9.40)	(2.91)	(3.20)	(6.11)
9	<b>Net Profit/(Loss) from ordinary activities after tax (7+8)</b>	<b>-150.72</b>	<b>24.83</b>	<b>-16.98</b>	<b>7.85</b>	<b>-256.05</b>	<b>1.97</b>	<b>6.85</b>	<b>8.82</b>
10	Other Comprehensive Income / (expenses) for the year, net of tax	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
11	<b>Total Comprehensive Income/(Loss) Net of Tax (9+10)</b>	<b>-150.72</b>	<b>24.83</b>	<b>-16.98</b>	<b>7.85</b>	<b>-256.05</b>	<b>1.97</b>	<b>6.85</b>	<b>8.82</b>
12	Paid up Equity share capital (face value of Rs.10/-)	631.20	631.20	631.20	631.20	631.20	631.20	631.20	631.20
13	Reserve excluding Revaluation reserve								
14	Earning per share of (before extra ordinary items) Rs.10 Each (Not Annualised)								
	a) Basic (Rs.)	-2.39	0.39	-0.27	0.12	-4.06	0.03	0.11	0.14
	b) Diluted (Rs.)	-2.39	0.39	-0.27	0.12	-4.06	0.03	0.11	0.14
	Earning per share of after extra ordinary items) Rs.10 Each (Not Annualised)								
	a) Basic (Rs.)	-2.39	0.39	-0.27	0.12	-4.06	0.03	0.11	0.14
	b) Diluted (Rs.)	-2.39	0.39	-0.27	0.12	-4.06	0.03	0.11	0.14

For and on behalf of Board of Directors

Vanta Bioscience Limited

*M. Daperla*

Dopesh Raja Mulakala  
Managing Director



Place : Hyderabad

Date : 10.08.2023

**VANTA BIOSCIENCE LIMITED**  
**NO.02/G/308/G NO.3/FF/SF/1-20-248 UMAJAY COMPLEX RASOOLPURA SECUNDERABAD - 500003**  
**CIN L74999TG2016PLC109280**

STATEMENT OF ASSETS & LIABILITIES AS ON 30th SEPTEMBER 2022

Sr.No.	Particulars	STANDALONE		CONSOLIDATED	
		30.09.2022	31.03.2022	30.09.2022	31.03.2022
		Un Audited	Audited	Un Audited	Audited
<b>A</b>	<b>Equity and Liabilities</b>				
1	<b>EQUITY</b>				
	a) Equity share capital	631.20	631.20	631.20	631.20
	b) Reserve & Surplus	1616.96	1767.68	1513.45	1769.50
	c) Non Controlling/Minority Interest	0.00	0.00	351.60	533.74
	<b>Sub total Equity</b>	<b>2248.16</b>	<b>2398.88</b>	<b>2496.25</b>	<b>2934.44</b>
	<b>LIABILITIES</b>				
2	<b>Non Current Liabilities</b>				
	a) Financial Liabilities				
	i) Borrowings	1272.77	1564.30	3602.35	3699.75
	b) Provisions		0.00	0.00	0.00
	c) Deferred tax Liabilities	79.77	78.36	87.76	78.36
	d) Other Non Current Liabilities		0.00	0.00	0.00
	<b>Sub Total -Non Current Liabilities</b>	<b>1352.55</b>	<b>1642.66</b>	<b>3690.11</b>	<b>3778.11</b>
3	<b>Current Liabilities</b>				
	a) Financial Liabilities				
	i) Borrowings	908.94	512.58	1109.84	786.93
	ii) Trade Payables	231.26	146.73	330.19	246.39
	b) Other Current Liabilities	437.82	339.15	742.16	390.66
	c) Provisions	0.00	0.00	0.00	3.87
	d) Current tax Liabilities(net)	0.00	0.00	0.00	0.00
	<b>Sub Total -Non Current Liabilities</b>	<b>1578.02</b>	<b>998.46</b>	<b>2182.18</b>	<b>1427.85</b>
	<b>Total Equity and Liabilities</b>	<b>5178.73</b>	<b>5040.00</b>	<b>8368.54</b>	<b>8140.40</b>
<b>B</b>	<b>ASSETS</b>				
1	<b>Non Current Assets</b>				
	a) Property, Plant and Equipment	1401.76	1453.52	3557.27	1453.52
	b) Capital Work in Progress	0.00		0.00	2278.03
	c) Other Intangible assets	2357.62	2158.63	2357.62	2158.63
	d) Other Intangible assets under development	0.00	0.00	772.53	568.81
	e) Investment in associates and joint ventres	0.00	0.00	0.00	0.00
	f) Financial Assets	0.00	0.00	0.00	0.00
	i) Investments in Subsidiary	300.00	300.00	0.00	0.00
	ii) Loans	0.00	0.00	0.00	0.00
	iii) Other Financial Assets	0.00	0.00	0.00	0.00
	g) Deferred tax assets (net)	0.00	0.00	0.00	0.00
	h) Other non current assets	27.48	27.48	181.62	231.62
	<b>Sub Total Non-CurrentAssets</b>	<b>4086.86</b>	<b>3939.63</b>	<b>6869.03</b>	<b>6690.61</b>
2	<b>Current Assets</b>				
	a) Inventories	730.06	723.55	730.06	723.55
	<b>b) Financial Assets</b>				
	i) Investments	0.00	0.00	0.00	0.00
	ii) Trade Receivable	73.89	72.30	124.61	113.41
	iii) Bank, Cash and Cash equivalents	6.72	6.91	9.02	22.42
	iv) Loans & Advances	211.97	233.75	565.20	518.37
	iv) Othe Financial Assets	0.00	0.00	0.00	0.00
	c) Current Tax Assets (net)	0.00	0.00	0.00	0.00
	d) Other Current Assets	69.24	63.86	70.63	72.04
	<b>Sub Total Current Assets</b>	<b>1091.87</b>	<b>1100.37</b>	<b>1499.51</b>	<b>1449.79</b>
	<b>Total Assets</b>	<b>5178.73</b>	<b>5040.00</b>	<b>8368.54</b>	<b>8140.40</b>

For and on behalf of Board of Directors

*Dopesh Raja*  
Dopesh Raja Mulakala  
Managing Director  
DIN:01176660



Place : Hyderabad  
Date : 10.08.2023

**VANTA BIOSCIENCE LIMITED**  
Cash Flow statement for the period ended 30th SEPTEMBER,2022

Particulars	(Rupees in Lacs)			
	STANDALONE		CONSOLIDATED	
	For the Half Year ended 30.09.2022	For the Year ended 31.03.2022	For the Half Year ended 30.09.2022	For the Year ended 31.03.2022
<b>A. Cash Flow from Operating Activities</b>				
Profit before exceptional , Extraordinary items and Tax	(149.30)	13.96	(432.95)	22.84
<b>Adjustment for:</b>				
Depreciation	62.44	131.61	131.08	131.61
Finance Charges	119.75	211.38	248.21	234.70
Profit on Sale of Fixed Assets	-	-	-	-
<b>Sub total</b>	<b>182.18</b>	<b>342.99</b>	<b>379.29</b>	<b>366.31</b>
<b>Operating profit Before Working Capital Changes</b>	<b>32.88</b>	<b>356.95</b>	<b>(53.67)</b>	<b>389.15</b>
<b>Adjustment for:</b>				
(Increase) /Decrease in Inventories	-6.50	252.87	(6.50)	252.87
(Increase) /Decrease in Trade receivables	-1.58	125.63	(11.20)	88.07
Increase /(Decrease) in Current Liabilities	183.20	52.26	435.59	(30.04)
(Increase) /Decrease Loans & Advances	16.39	(117.45)	(46.84)	(172.18)
(Increase) /Decrease Current Assets	-	-	51.41	-
(Increase) /Decrease in Current Investment	-	-	-	-
<b>Sub total</b>	<b>191.51</b>	<b>313.31</b>	<b>422.46</b>	<b>138.72</b>
<b>Cash Generated from operations</b>	<b>224.39</b>	<b>670.26</b>	<b>368.80</b>	<b>527.87</b>
<b>Net Cash Flow from Operating Activities</b>	<b>224.39</b>	<b>670.26</b>	<b>368.80</b>	<b>527.87</b>
<b>B: Cash Flow from Investing Activities</b>				
Purchase of Fixed Assets	-209.67	(805.23)	(2,433.82)	(33.21)
Capital Work In progress	-	-	2,074.31	(1,684.86)
Capital Work In progress-R&D	-	-	-	-
proceeds from sale of Fixed Assets	-	-	-	-
Investment in Subsidiaries	-	-	-	-
Purchase of other Non current Investments	-	-	-	-
<b>Net Cash Flow from Investing Activities</b>	<b>-209.67</b>	<b>(805.23)</b>	<b>(359.51)</b>	<b>(1,718.07)</b>
<b>C: Cash Flow from Financing Activities</b>				
Increase /(Decrease) in Unsecured Loan	-	-	-	243.23
Increase /(Decrease) in Working capital	48.41	209.36	-	-33.15
Increase /(Decrease) in Term Loan	56.42	139.62	-	679.62
Increase /(Decrease) in Long Term Borrowings	-	-	(97.40)	-
Increase /(Decrease) in Short Term Borrowings	-	-	322.90	-
Increase /(Decrease) in share capital	-	-	-	298.23
Increase /(Decrease) in share Premium	-	-	-	-
Finance Charges	-119.75	(211.38)	(248.21)	(234.70)
<b>Net Cash Flow from Financing Activities</b>	<b>-14.92</b>	<b>137.60</b>	<b>(22.70)</b>	<b>953.23</b>
Actual Payment of Income Tax	0.00	(2.38)	-	(5.64)
<b>D: Net Increase/Decrease in Cash and cash Equivalents</b>	<b>(0.19)</b>	<b>0.24</b>	<b>(13.41)</b>	<b>(242.61)</b>
<b>Opening of Cash &amp; Cash Equivalents</b>	<b>6.91</b>	<b>6.67</b>	<b>22.42</b>	<b>265.03</b>
<b>Closing Balance of Cash &amp; Cash Equivalents</b>	<b>6.72</b>	<b>6.91</b>	<b>9.02</b>	<b>22.42</b>

See accompanying notes to the financial statements  
As per our report of even date annexed.

Place : Hyderabad  
Date : 10.08.2023

For and on behalf of Board of Directors

*M. Dopesh*

Dopesh Raja Mulakata  
Managing Director  
DIN:01176660



### **Notes to Standalone and consolidated financial statements:**

1. The above said financial results were reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 10<sup>th</sup> August, 2023.
2. The Statutory Auditors have carried out limited review of the Un Audited Results of the company for the half year ended 30.09.2022.
3. The statement are prepared in accordance with the requirements of accounting standards (AS) specified under section 133 of Companies Act, 2013 read with rule 7 of the Companies (Accounts) Rules 2014.
4. As per MCA Notification dated 16th February 2015, the companies whose shares are listed on BSE SME platform as referred to in chapter XB of SEBI (Issue of Capital and Disclosure requirements) regulations, 2009 are exempted from the Compulsory requirement of adoption of IND—AS. As the company is covered under exempted from the Compulsory requirement of adoption of IND As. Hence it has not adopted IND AS for preparation of Financial Statements.
5. Statement of Assets and Liabilities as on 30<sup>th</sup> September 2022 is enclosed herewith.
6. Statement of Cash flow for the period ended 30<sup>th</sup> September 2022 is enclosed herewith.
7. The financial figures for the previous half year/year have been regrouped/reclassified wherever necessary to confirm to current period.
8. The Company is engaged in the business of full service preclinical contract Research organization. Hence there is no separate segment reporting required
9. The said results are uploaded on the website of the Company [www.vantabio.com](http://www.vantabio.com) and on BSE Ltd.
10. NCLT, Hyderabad vide their order dated 27.04.2022 has admitted the application of Operational Creditor and has approved the Corporate Insolvency Resolution Process ("CIRP"). The Operational Creditor has alleged for total amount of due including principal and interest of Rs. 1,18,65,000/-. The Company has settled the entire dispute with the operational creditor in the Supreme Court by agreeing to pay an amount of Rs. 90,00,000/- in 4 installments by 15.05.2023.






**Independent Auditor's Limited Review Report on unaudited consolidated half yearly  
and year to date financial results of the Company**

**To The Board of Directors of  
Vanta Bioscience Limited**

1. We have reviewed the accompanying statement of Consolidated Unaudited Financial Results of Vanta Bioscience Limited ("the Parent") and its subsidiaries (the parent and its subsidiaries together referred as "the Group") for the half year ended on 30<sup>th</sup> September, 2022 ("the statement"), being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This statement is the responsibility of the Parent's Management and has been approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principle laid down in the Accounting Standard 25 "Interim Financial Reporting" ("AS 25"), prescribed under Section 133 of the companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the results of the following entities:
  - a. Vanta Bioscience Limited- Parent Company
  - b. Vanta Clinical Research Limited- Subsidiary Company
  - c. Vayam Research Solutions Limited-Step Down Subsidiary Company
5. ***NCLT, Hyderabad vide their order dated 27.04.2022 has admitted the application of Operational Creditor and has approved the Corporate Insolvency Resolution Process ("CIRP"). The Operational Creditor has alleged for total amount of due including principal and interest of Rs. 1,18,65,000/-. The Company has settled the entire dispute with the operational creditor in the Supreme Court by agreeing to pay an amount of Rs. 90,00,000/- in 4 installments by 15.05.2023. Our opinion is not modified in respect of this matter.***





**MATHESH & RAMANA**  
CHARTERED ACCOUNTANTS

6. Based on our review conducted and procedure performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditors referred to in paragraph 7 below, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended including the manner in which it is to be disclosed, or that it contains any material misstatement.
7. The consolidated unaudited financial results includes the interim financial statements/ financial information/ financial results of 2 subsidiaries which have not been reviewed/audited by their auditors, whose interim financial statements/ financial information/ financial results reflect total assets of Rs. 3,642.22 Lakhs as at September 30, 2022, total revenues of Rs. 112.34 Lakhs for the half year ended September 30, 2022, total net profit after tax of Rs. (291.63) Lakhs and cash flows (net outflow) of Rs. (13.22) Lakhs for the period from 1<sup>st</sup> April, 2022 to 30<sup>th</sup> September, 2022, as considered in the consolidated unaudited financial results. According to the information and explanations given to us by the Management, these interim financial statements / financial information / financial results are not material to the Group.

Our conclusion on the Statement is not modified in respect of the above matters.

For **MATHESH & RAMANA**  
CHARTERED ACCOUNTANTS



**B V RAMANA REDDY**  
M. No. 026967 Partner

Place: Hyderabad

Date: 10.08.2023

**UDIN: 23026967BGUSDD5764**






**Independent Auditor's Limited Review Report on unaudited standalone half yearly and year to date financial results of the Company**

**To The Board of Directors of  
Vanta Bioscience Limited**

1. We have reviewed the accompanying statement of Unaudited Standalone Financial Results of Vanta Bioscience Limited ("the Company") for the half year ended on 30<sup>th</sup> September, 2022 ("the statement"). This statement is the responsibility of the Company's Management and has been approved by the Company's Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.
2. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. *NCLT, Hyderabad vide their order dated 27.04.2022 has admitted the application of Operational Creditor and has approved the Corporate Insolvency Resolution Process ("CIRP"). The Operational Creditor has alleged for total amount of due including principal and interest of Rs. 1,18,65,000/-. The Company has settled the entire dispute with the operational creditor in the Supreme Court by agreeing to pay an amount of Rs. 90,00,000/- in 4 installments by 15.05.2023. Our opinion is not modified in respect of this matter.*
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Our conclusion on the Statement is not modified in respect of the above matters.

For **MATHESH & RAMANA**  
CHARTERED ACCOUNTANTS



**B V RAMANA REDDY**  
M. No. 026967 Partner

Place: Hyderabad

Date: 10.08.2023

UDIN: 23026967BGUSDC6852 E-mail : mateshca@yahoo.co.in